U.S. Markets open in 56 mins.

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
112.92-0.92 (-0.81%)
At close: 4:00PM EDT

112.90 -0.02 (-0.02%)
Pre-Market: 6:58AM EDT

People also watch
Full screen
Previous Close113.84
Bid110.50 x 300
Ask114.00 x 100
Day's Range108.12 - 117.44
52 Week Range31.38 - 117.44
Avg. Volume1,207,464
Market Cap10.36B
PE Ratio (TTM)-22.04
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal1 hour ago

    [$$] Alnylam's New Medicine To Enter Pricing Debate

    Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.

  • Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
    Investor's Business Daily16 hours ago

    Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance

    Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.

  • Barrons.com17 hours ago

    Alnylam Pharmaceuticals: Bet or Fold?

    When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.